ATE404208T1 - Uridin-therapie für patienten mit erhöhten purin- werten - Google Patents

Uridin-therapie für patienten mit erhöhten purin- werten

Info

Publication number
ATE404208T1
ATE404208T1 AT01979786T AT01979786T ATE404208T1 AT E404208 T1 ATE404208 T1 AT E404208T1 AT 01979786 T AT01979786 T AT 01979786T AT 01979786 T AT01979786 T AT 01979786T AT E404208 T1 ATE404208 T1 AT E404208T1
Authority
AT
Austria
Prior art keywords
patients
purine levels
uridine
elevated purine
elevated
Prior art date
Application number
AT01979786T
Other languages
English (en)
Inventor
Theodore Page
Deborah Brewer
Charles Moseley
Original Assignee
Repligen Corp
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24768963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE404208(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repligen Corp, Univ California filed Critical Repligen Corp
Application granted granted Critical
Publication of ATE404208T1 publication Critical patent/ATE404208T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT01979786T 2000-10-12 2001-10-12 Uridin-therapie für patienten mit erhöhten purin- werten ATE404208T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/689,551 US6727231B1 (en) 2000-10-12 2000-10-12 Uridine therapy for patients with elevated purine levels

Publications (1)

Publication Number Publication Date
ATE404208T1 true ATE404208T1 (de) 2008-08-15

Family

ID=24768963

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01979786T ATE404208T1 (de) 2000-10-12 2001-10-12 Uridin-therapie für patienten mit erhöhten purin- werten

Country Status (8)

Country Link
US (1) US6727231B1 (de)
EP (1) EP1324761B1 (de)
JP (1) JP2004527460A (de)
AT (1) ATE404208T1 (de)
AU (2) AU1171102A (de)
CA (1) CA2425593A1 (de)
DE (1) DE60135358D1 (de)
WO (1) WO2002030354A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US7440590B1 (en) * 2002-05-21 2008-10-21 University Of Kentucky Research Foundation System and technique for retrieving depth information about a surface by projecting a composite image of modulated light patterns
CA2542023A1 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
WO2005034874A2 (en) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
US20090215714A1 (en) * 2004-06-10 2009-08-27 Perry Renshaw Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder
US7737128B2 (en) * 2004-06-10 2010-06-15 The Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
WO2006020703A1 (en) * 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
CA2580236A1 (en) * 2004-09-17 2006-03-23 Kissei Pharmaceutical Co., Ltd. Purinenucleoside derivative modified in 8-position and medical use thereof
US20060079582A1 (en) * 2004-09-23 2006-04-13 Jeffrey Jonas Memantine for the treatment of childhood behavioral disorders
JP4778946B2 (ja) * 2007-12-03 2011-09-21 明治飼糧株式会社 血中尿酸値低下剤
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
IT1219667B (it) 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
IL108524A0 (en) 1993-02-03 1994-05-30 Gensia Inc Imidazodiazepine analogs
US5962459A (en) 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
DE69941586D1 (de) * 1998-07-31 2009-12-03 Massachusetts Inst Technology Verwendung von Uridin in Kombination mit Cholin zur Behandlung von Gedächtnisstörungen
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
CA2362925C (en) * 1999-02-23 2011-04-12 Regents Of The University Of California Methods of treatment of mitochondrial disorders

Also Published As

Publication number Publication date
CA2425593A1 (en) 2002-04-18
AU2002211711B2 (en) 2007-05-17
US6727231B1 (en) 2004-04-27
EP1324761A2 (de) 2003-07-09
DE60135358D1 (de) 2008-09-25
JP2004527460A (ja) 2004-09-09
EP1324761A4 (de) 2004-09-08
WO2002030354A3 (en) 2002-07-11
EP1324761B1 (de) 2008-08-13
WO2002030354A2 (en) 2002-04-18
AU1171102A (en) 2002-04-22

Similar Documents

Publication Publication Date Title
HK1069767A1 (en) Methods for inhibiting ocular processes
DK1955700T3 (da) Terapeutisk behandling af androgenreceptor-betingede lidelser
DE60037578D1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
BR0211986A (pt) 29-enóis de rapamicina
BR9916896A (pt) Diaril aminas substituìdas com 1-heterociclo
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
ATE320457T1 (de) Polyurethanlösungen mit alkoxysilanstruktureinheiten
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
NO20041917D0 (no) Spesifikke midler som binder humant angiopoietin-2
DE69737592D1 (de) Mittel gegen juckreiz
NO20054343L (no) Behandling av immunologiske lidelser ved anvendelse av agonister av interleukin-21/interleukin-21 reseptor
ATE449840T1 (de) Alpha-amylasevariante mit veränderten eigenschaften
ATE394121T1 (de) Verwendung von antikörpern gegen das muc18- antigen
HK1112941A1 (en) Use of a33 antigens and jam-it a33
MXPA04002562A (es) Combinacion de un pde-4 y nsaid.
ATE404208T1 (de) Uridin-therapie für patienten mit erhöhten purin- werten
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
DE60332096D1 (de) Mikrosatellitenmarker in form von mononukleotidwiederholungen zur detektion von mikrosatelliteninstabilität
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
NO20053903D0 (no) Nukleotidlipidesterderivater.
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
YU89103A (sh) Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a
EP1254260A4 (de) Methoden zur diagnose und behandlung von herzkrankheiten
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
DE69923559D1 (de) Methoden zur inhibierung von helicobacter pylori

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties